2578 Journal of Medicinal Chemistry, 2008, Vol. 51, No. 8
Brief Articles
2
3
3
(dd, 1H, J ) 14.1 Hz, J ) 4.2 Hz, H3), 5.38 (dd, 1H, J ) 9.4
Acknowledgment. This work was financially supported by
grants from le Centre National de la Recherche Scientifique
(CNRS), l’Agence Nationale de la Recherche contre le Sida
(ANRS), and the European Commission (Grant LSHB-CT-2003-
503480). The European TRIoH Consortium is gratefully ac-
knowledged. The mass spectrometry facility used in this study
was funded by the European Community (FEDER), the Région
Nord-Pas de Calais (France), the CNRS, and the Université des
Sciences et Technologies de Lille. We are grateful to Martine
Michiels, Nam Joo Vanderveken, and Barbara Van Remoortel
for excellent technical assistance.
3
3
Hz, J ) 4.2 Hz, H2), 6.26 (d, 1H, J ) 15.8 Hz, HR), 6.89 (d,
1H, J ) 8.2 Hz, H5′′), 7.01 (s, 1H, H2′), 7.06 (dd, 1H, J ) 8.2
3
3
4
4
Hz, J ) 2.0 Hz, H6′′), 7.18 (d, 1H, J ) 2.0 Hz, H2′′), 7.55 (d,
1H, 3J ) 15.8 Hz, Hꢀ), 7.61 (s, 1H, H5′); 13C NMR 171.2 (COOH),
166.7 (CdO), 151.2 (C3′), 149.1 (C4′′), 146.8 (C3′′), 146.4 (Cꢀ),
145.2 (C4′), 142.3 (C6′), 127.5 (C1′′), 126.0 (C1′), 122.8 (C6′′),
120.0 (C2′), 116.5 (C5′′), 115.3 (CR), 114.7 (C2′′), 113.3 (C5′),
72.7 (C2), 35.1 (C3); MS (EI) 404 (M+0 - 1, 57%), 242 (lactic
fragment, 100%), 180 (caffeic fragment, 50%); HRMS (nano-ESI-
FT-ICR)(negative mode) calcd for C18H15NO10 404.062 32, found
404.062 33. Anal. (C18H15NO10) C, H, N.
1
3: RD (MeOH) +25.3 ° (c 0.21 g/L); mp 45–46 °C; H NMR
Supporting Information Available: Additional chemical and
biological information. This material is available free of charge
2
3
(acetone-d6) 3.36 (dd, 1H, J ) 13.9 Hz, J ) 9.0 Hz, H3), 3.69
2
3
3
(dd, 1H, J ) 13.9 Hz, J ) 4.3 Hz, H3), 5.40 (dd, 1H, J ) 9.0
3
3
Hz, J ) 4.3 Hz, H2), 6.33 (d, 1H, J ) 15.9 Hz, HR), 6.98 (s,
1H, H2′), 7.23 (s, 1H, H2′′), 7.58 (s, 1H, H5′), 7.61 (s, 1H, H5′′),
8.12 (d, 1H, J ) 15.9 Hz, Hꢀ); 13C NMR 170.9 (COOH), 166.0
3
References
(1) Petersen, M.; Simmonds, M. S. Rosmarinic acid. Phytochemistry 2003,
62, 121–125.
(2) Ono, K.; Hasegawa, K.; Naiki, H.; Yamada, M. Curcumin has potent
anti-amyloidogenic effects for Alzheimer’s beta-amyloid fibrils in vitro.
J. Neurosci. Res. 2004, 75, 742–750.
(3) Alkam, T.; Nitta, A.; Mizoguchi, H.; Itoh, A.; Nabeshima, T. A natural
scavenger of peroxynitrites, rosmarinic acid, protects against impair-
ment of memory induced by Aꢀ25–35. BehaV. Brain Res. 2007, 180,
139–145.
(CdO), 151.5 (C3′′), 151.1 (C3′), 147.8 (C4′′), 145.1 (C4′), 142.8
(Cꢀ), 142.6 (C6′′) 142.2 (C6′), 125.8 (C1′), 124.4 (C1′′), 120.3
(CR), 120.0 (C2′), 115.4 (C2′′), 113.3 (C5′), 113.1 (C5′′), 73.0 (C2),
35.1 (C3); MS (EI) 449 (M+0 - 1, 45%), 242 (lactic fragment,
100%), 226 (caffeic fragment, 52%); HRMS (nano-ESI-FT-ICR)
(negative mode) calcd for C18H14N2O12 449.047 40, found 449.043 22.
Anal. (C18H14N2O12) C, H, N.
Integrase Inhibition (Protocol 1). To determine the susceptibil-
ity of the HIV-1 integrase enzyme toward different compounds,
we used an enzyme-linked immunosorbent assay. This assay uses
an oligonucleotide substrate of which one oligo (5′-ACTGCTA-
GAGATTTTCCACACTGACTAAAAGGGTC-3′) is labeled with
biotin on the 3′ end and the other oligo is labeled with digoxigenin
at the 5′ end. For the overall integration assay the second
5′-digoxigenin labeled oligo is 5′-GACCCTTTTAGTCAGTGTG-
GAAAATCTCTAGCAGT-3′. The integrase was diluted in 750
mM NaCl, 10 mM Tris, pH 7.6, 10% glycerol, and 1 mM
ꢀ-mercaptoethanol. To perform the reaction, 4 µL of diluted
integrase (corresponds to 1.6 µM WT integrase22) and 4 µL of
annealed oligos (7 nM) were added to a final reaction volume of
40 µL containing 10 mM MgCl2, 5 mM DTT, 20 mM HEPES, pH
7.5, 5% PEG, and 15% DMSO. The reaction was carried out for
1 h at 37 °C. These reactions were followed by an immunosorbent
assay on avidin coated plates.28
Integrase Inhibition (Protocol 2). Oligonucleotides were pur-
chased from Eurogentec and further purified on 18% acrylamide/
urea denaturing gel: U5B, GTGTGGAAAATCTCTAGCA; U5A,
5′-ACTGCTAGAGATTTTCCACAC. Wild-type HIV-1 integrase
was purified as described previously.29 The assay was performed
in a reaction volume of 20 µL containing 0.025 pmol of labeled
U5A/U5B double-stranded DNA substrate and 1 pmol of integrase
in buffer [20 mM HEPES (pH 7.2), 10 mM MgCl2, 25 mM NaCl,
and 1 mM DTT]. Products were separated on an 18% acrylamide/
urea denaturing gel and quantified on a phosphoimager using
ImageQuant software (Amersham Pharmacia Biotech).
In Vitro Anti-HIV and Drug Susceptibility Assays. The
inhibitory effect of antiviral drugs on the HIV-1-induced cytopathic
effect (CPE) in human lymphocyte MT-4 cell culture was deter-
mined by the MT-4/MTT-assay.30 This assay is based on the
reduction of the yellow 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT) by mitochondrial dehydrogenase of
metabolically active cells to a blue formazan derivative, which can
be measured spectrophotometrically. The 50% cell culture infective
dose (CCID50) of the HIV-1 (IIIB) strain was determined by titration
of the virus stock using MT-4 cells. For the drug susceptibility
assays MT-4 cells were infected with 100–300 CCID50 of the virus
stock in the presence of 5-fold serial dilutions of the antiviral drugs.
The concentrations of various compounds achieving 50% protection
against the CPE of the different HIV strains, which are defined as
EC50, were determined. In parallel the 50% cytotoxic concentration
(CC50) was determined.
(4) Ono, K.; Yamada, M. Antioxidant compounds have potent anti-
fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils
in vitro. J. Neurochem. 2006, 97, 105–115.
(5) Masuda, M.; Suzuki, N.; Taniguchi, S.; Oikawa, T.; Nonaka, T.;
Iwatsubo, T.; Hisanaga, S.; Goebert, M.; Hasegawa, M. Small molecule
inhibitors of R-synuclein assembly. Biochemistry 2006, 45, 6085–6094.
(6) Jelie, D.; Mildner, B.; Kootrun, S.; Nujie, K.; Verbanac, D.; Culie,
O.; Antolovie, R.; Brandt, W. Homology modeling of human fyn
kinase structure: discovery of rosmarinic acid as a new fyn kinase
inhibitor and in silico study of its possible binding modes. J. Med.
Chem. 2007, 50, 1090–1100.
(7) Hur, Y.-G.; Yun, Y.; Won, J. Rosmarinic acid induces p56lck-
dependent apoptosis in Jurkat and peripheral T cells via mitochondrial
pathway independent from Fas/Fas ligand interaction. J. Immunol.
2004, 172, 79–87.
(8) Koukoulitsa, C.; Zika, C.; Geromichalos, G. D.; Demopoulos, V. J.;
Skaltsa, H. Evaluation of aldose reductase inhibition and docking
studies of some secondary metabolites, isolated from Origanum
Vulgare L. ssp. hirtum. Bioorg. Med. Chem. 2006, 14, 1653–1659.
(9) Qiao, S.; Li, W.; Tsubouchi, R.; Haneda, M.; Murakami, K.; Takeuchi,
F.; Nisimoto, Y.; Yoshino, M. Rosmarinic acid inhibits the formation
of reactive oxygen and nitrogen species in RAW264.7 macrophages.
Free Radical Res. 2005, 39, 995–1003.
(10) Yamasaki, K.; Nakano, M.; Kawahata, T.; Mori, H.; Otake, T.; Ueba,
N.; Oishi, I.; Inami, R.; Yamane, M.; Nakamura, M.; Murata, H.;
Nakanishi, T. Anti-HIV-1 activity of herbs in Labiatae. Biol. Pharm.
Bull. 1998, 21, 829–833.
(11) Kageyama, S.; Kurokawa, M.; Shiraki, K. Extract of Prunella Vulgaris
spikes inhibits HIV replication at reverse transcription in vitro and
can be absorbed from intestine in vivo. AntiViral Chem. Chemother.
2000, 11, 157–164.
(12) Tewtrakul, S.; Miyashiro, H.; Nakamura, N.; Hattori, M.; Kawahata,
T.; Otake, T.; Yoshinaga, T.; Fujiwara, T.; Supavita, T.; Yuenyong-
sawad, S.; Rattanasuwon, P.; Dej-Adisai, S. HIV-1 integrase inhibitory
substances from Coleus parVifolius. Phytother. Res. 2003, 17, 232–
239.
(13) Mazumder, A.; Neamati, N.; Sunder, S.; Schulz, J.; Pertz, H.; Eich,
E.; Pommier, Y. Curcumin analogs with altered potencies against
HIV-1 integrase as probes for biochemical mechanisms of drug action.
J. Med. Chem. 1997, 40, 3057–3063.
(14) Lim, Y. A.; Kojima, S.; Nakamura, N.; Miyashiro, H.; Fushimi, H.;
Komatsu, K.; Hattori, M.; Shimotohno, K.; Gupta, M. P.; Correa, M.
Inhibitory effects of Cordia spinescens extracts and their constituents
on reverse transcriptase and protease from human immunodeficiency
virus. Phytother. Res. 1997, 11, 490–495.
(15) Hooker, C. W.; Lott, W. B.; Harrich, D. Inhibitors of human
immunodeficiency virus type 1 reverse transcriptase target distinct
phases of early reverse transcription. J. Virol. 2001, 75, 3095–3104.
(16) Duncan, C.; Dougall, H.; Johnston, P.; Green, S.; Brogan, R.; Leifert,
C.; Smith, L.; Golden, M.; Benjamin, N. Chemical generation of nitric
oxide in the mouth from the enterosalivary circulation of dietary nitrate.
Nat. Med. 1995, 1, 546–551.